title: Chemo-radiotherapy for stage III unresectable non-small cell lung cancer long-term results of a prospective study.
abstract: BACKGROUND
  Combined-modality treatment is considered standard of care in the treatment of stage III non-small-cell lung cancer (NSCLC). This study was designed to assess the efficacy and tolerability of induction paclitaxel/carboplatin followed by concurrent thoracic radiotherapy and weekly paclitaxel.
  
  
  METHODS
  Patients with unresectable stage III NSCLC were treated prospectively with two cycles of paclitaxel (175 mg/m2) and carboplatin (area under the curve of 6) followed by radiotherapy (60-66 Gy) concurrent with 6 weekly doses of paclitaxel (60 mg/m2). Response was determined 8 weeks after the completion of treatment and treatment-related toxicities were assessed at each visit during treatment and follow-up.
  
  
  RESULTS
  Sixty-three patients were treated, 5 had complete response and 33 had partial response, giving a response rate of 60%. Thirty-seven percent of patients developed grade 3 or 4 neutropenia; 48% had significant esophagitis requiring the use of narcotic analgesics. Two patients developed esophageal stricture subsequently. The median survival was 51 months and 12 months for stage IIIA and IIIB patients, respectively. Progression-free survival was 16 months and 11 months respectively.
  
  
  CONCLUSIONS
  The response rate was encouraging. Esophagitis was a significant morbidity and should prompt modification of treatment regimen, either in the chemotherapy schedule or by adjusting the radiotherapy treatment planning.
authors.affiliation: Department of Medical Oncology, National Cancer Centre, 11 Hospital Drive, Singapore 169610, Singapore. dmolss@nccs.com.sg
authors.forename: Swan Swan
authors.initials: SS
authors.lastname: Leong
authors.forename: Kam Weng
authors.initials: KW
authors.lastname: Fong
authors.forename: Yew Kwang
authors.initials: YK
authors.lastname: Ong
authors.forename: Kian Fong
authors.initials: KF
authors.lastname: Foo
authors.forename: Peter
authors.initials: P
authors.lastname: Ang
authors.forename: Joseph
authors.initials: J
authors.lastname: Wee
authors.forename: Khai Mun
authors.initials: KM
authors.lastname: Lee
authors.forename: Eng Huat
authors.initials: EH
authors.lastname: Tan
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004941:Esophagitis / Q000209:etiology; D005260:Female; D006402:Hematologic Diseases / Q000209:etiology; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D011446:Prospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D016190:Carboplatin; D017239:Paclitaxel